Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…Abstract Number: 1080 • 2015 ACR/ARHP Annual Meeting
Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: The modified Rodnan skin score (mRSS) is the major outcome measure for skin fibrosis in clinical trials (CT) in diffuse cutaneous scleroderma (dcSSc). Traditionally,…Abstract Number: 1887 • 2015 ACR/ARHP Annual Meeting
Deficiency in Micronutrients Is a Frequent Burden in Patients with Systemic Sclerosis
Background/Purpose: Micronutrients are essential dietary factors involved in many metabolic processes, including oxidative stress, collagen synthesis and wound healing, which are key aspects of the…Abstract Number: 1895 • 2015 ACR/ARHP Annual Meeting
Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease involving the skin and visceral organs, most commonly the gastrointestinal tract and lungs. Interstitial lung disease…Abstract Number: 1912 • 2015 ACR/ARHP Annual Meeting
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and fibrosis of the skin and various internal organs. Glycyrrhizin, a triterpenoid saponin…Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…Abstract Number: 3002 • 2014 ACR/ARHP Annual Meeting
Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis
Background/Purpose Systemic sclerosis (SSc) is an irreversible fibrotic disorder with interstitial lung disease (ILD) being a major complication and leading cause of mortality. African American…Abstract Number: 2704 • 2014 ACR/ARHP Annual Meeting
Fatigue in Systemic Sclerosis
Background/Purpose: Fatigue is a frequently reported disabling symptom for patients with systemic sclerosis (SSc). It has a major impact on overall quality of life including…Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…Abstract Number: 1721 • 2014 ACR/ARHP Annual Meeting
Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis
Background/Purpose: Stem cell factor (SCF) is a potential driving factor in the development of systemic sclerosis (SSc) and a possible therapeutic target. SCF is a…Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…Abstract Number: 742 • 2014 ACR/ARHP Annual Meeting
Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer
Background/Purpose Ultrasound has been used to measure scleroderma skin thickness, but it has not been established that routine clinical ultrasound equipment is adequate. We compared skin…
